scabies
Conditions
Interventions
As a preparation for the use of Ivermectin bath method, 4 tablets of Stromectol Tablets 3mg is dissolved in baby bath powder contained hot tub water of 150L. Then, one takes a bath in the prepared tub
Sponsors
Laboratory of medical safety management, Tokyo University of Science
Tsubasa clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Patient diagnosed as scabies - Patient who belongs in a care service facility of a medical monitoring by specialized physician - Patient who signed, based on his/her free will, to the clinical trial agreement with full understanding of the purpose of this conducted trial and its insights.
Exclusion criteria
Exclusion criteria: 1) Patient diagnosed with a skin disorder and thus has skin barrier problem 2) One who has had the experience of the following; - Hepatic disease - The disease considered to affect the test results by doctor in attendance. - The disease considered that use of Ivermectin results detrimental to the patient. 3) one with excessive consumption of caffeine contained coffee or drink (>8 cups / day) 4) abuser of medication or alcohol 5) The addict of an illegal drug 6) One who has contributed 200mL blood within 4 weeks before the trial, or male contributed 400mL blood within 12 weeks and female contributed 400mL blood within 16 weeks 7) One who participated in other clinical trials with the use of study medication within 4 weeks before the trial 8) One who has an anamnesis of hypersensitivity for the ingredients contained in Stromectol Tablets or in the baby bath powder (Pigeon, Inc.) 9) Pregnant female or lactating woman or child under 15kg weight 10) One whom the doctor considered to be unsuitable for this clinical trial
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Analysis of Ivermectin concentration in stratum corneum and blood after the use of Ivermectin bath method. | — |
Primary
| Measure | Time frame |
|---|---|
| Monitoring the early symptoms of adverse effects of the Ivermectin bath method as its safety assessment. | — |
Countries
Japan
Contacts
Public ContactMasayo Komoda
Tokyo University of Science Faculty of Pharmaceutical Sciences
Outcome results
None listed